Enterome
Muriel Mas has worked as a Clinical Development Project Leader at Enterome since 2017. In this role, they lead and guides a cross-functional team to ensure the timely and high-quality delivery of study outputs, adhering to internal SOPs, GCP, and regulatory guidelines. Currently, they are leading a First in Human clinical study for patients with advanced or recurrent glioblastoma and a phase I-II clinical study in adrenal cancer. Prior to working at Enterome, Muriel worked as a Clinical Projects Leader in Onco-urology at Unicancer from 2008 to 2017.
Muriel Mas has attended Université Paris-Est Créteil (UPEC) for an unknown duration of time.
This person is not in the org chart
Enterome
Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.